Wesbanco Bank Inc. Acquires Shares of 64,000 Intellia Therapeutics, Inc. $NTLA

Wesbanco Bank Inc. acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 64,000 shares of the company’s stock, valued at approximately $575,000. Wesbanco Bank Inc. owned 0.06% of Intellia Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. raised its position in Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after purchasing an additional 808 shares during the period. CWM LLC raised its position in Intellia Therapeutics by 4.7% in the third quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after purchasing an additional 856 shares during the period. Comerica Bank increased its position in shares of Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after acquiring an additional 927 shares during the last quarter. Finally, Interchange Capital Partners LLC increased its position in shares of Intellia Therapeutics by 9.7% during the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock worth $202,000 after acquiring an additional 1,030 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $14.09 on Monday. The stock’s 50 day moving average price is $13.65 and its two-hundred day moving average price is $12.41. Intellia Therapeutics, Inc. has a 52-week low of $6.83 and a 52-week high of $28.25. The stock has a market capitalization of $1.70 billion, a P/E ratio of -3.68 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. During the same period in the previous year, the business earned ($1.27) EPS. The business’s quarterly revenue was up 78.4% on a year-over-year basis. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -3.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Wells Fargo & Company lifted their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 3rd. Citigroup reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 28th. Robert W. Baird lifted their target price on Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, April 27th. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Royal Bank Of Canada lifted their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a research report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Hold” and an average price target of $20.55.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.